Abstract
Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 47-52 |
| Number of pages | 6 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 45 |
| Issue number | 3 II |
| State | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Doxepin's effects on chronic pain and depression : A controlled study. / Hameroff, Stuart R; Weiss, J. L.; Lerman, J. C.
In: Journal of Clinical Psychiatry, Vol. 45, No. 3 II, 1984, p. 47-52.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Doxepin's effects on chronic pain and depression
T2 - A controlled study
AU - Hameroff, Stuart R
AU - Weiss, J. L.
AU - Lerman, J. C.
PY - 1984
Y1 - 1984
N2 - Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.
AB - Sixty patients with chronic pain in the low back or cervical spine concomitant with clinical depression were studied in a 6-week, randomized, double-blind comparison of doxepin and placebo. Significant improvements in the doxepin-treated group compared to placebo or to baseline values were seen on Hamilton depression scores. Global Assessment Scale scores, pain severity, percent of time pain felt, and effect of pain on activity, sleep, and muscle tension. Some improvements were observed after 1 week of treatment; the most improvement occurred at 6 weeks, when the mean doxepin dosage was approximately 200 mg/day and plasma doxepin and nordoxepin averaged 80 ng/ml. No significant harmful effects were observed. Neither plasma beta-endorphin nor enkephalin-like activity demonstrated significant differences from baseline. These data indicate that doxepin is a valuable treatment for patients with chronic pain and depression.
UR - http://www.scopus.com/inward/record.url?scp=0021280966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021280966&partnerID=8YFLogxK
M3 - Article
C2 - 6321454
AN - SCOPUS:0021280966
VL - 45
SP - 47
EP - 52
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
SN - 0160-6689
IS - 3 II
ER -